Plasma MRNA As Liquid Biopsy Predicts Chemo-sensitivity in Advanced Gastric Cancer Patients

Overview

Journal J Cancer

Specialty Oncology

Date 2017 Mar 7

PMID 28261345

Citations 6

Authors

Jie Shen

Weiwei Kong

Yuanna Wu

Haozhen Ren

Jia Wei

Yang Yang

Yan Yang

Lixia Yu

Wenxian Guan

Baorui Liu

Affiliations

Soon will be listed here.

Abstract

Predictive biomarkers based individualized chemotherapy can improve efficacy. However, for those advanced patients, it may be impossible to obtain the tissues from operation. Tissues from biopsy may not be always enough for gene detection. Thus, biomarker from blood could be a non-invasive and useful tool to provide real-time information in the procedure of treatment. To further understand the role of plasma mRNA in chemo-efficiency prediction, several mRNA expression levels were assessed in plasma and paired tumor tissues from 133 locally advanced gastric cancer patients (stage III), and mRNA levels were correlated with chemosensitivity to docetaxel, pemetrexed, platinum, and irinotecan. mRNA expression level in 64 advanced gastric cancer patients (stage IV) was also examined (55 in test group, and 9 in control), and chemotherapy in the test group were given according to the plasma gene detection. As a result, in the 133 patients with locally advanced gastric cancer (Stage III), correlations were observed between the mRNA expression of plasma/tumor BRCA1 levels and docetaxel sensitivity (P<0.001), plasma/tumor TS and pemetrexed sensitivity (P<0.001), plasma/tumor BRCA1 and platinum sensitivity (plasma, P=0.016; tumor, P<0.001), and plasma/tumor TOPO1 and irinotecan sensitivity (plasma, P=0.015; tumor, P=0.011). Among another 64 patients with advanced cancer (Stage IV), the median OS of test group was 15.5m (95% CI=10.1 to 20.9m), the PFS was 9.1m (95% CI=8.0 to 10.2m), which were significant longer than the control (P=0.047 for OS, P=0.038 for PFS). The mortality risk was higher in the control than patients treated according to the plasma gene detection (HR in the control=2.34, 95% CI=0.93 to 5.88, P=0.071). Plasma mRNA as liquid biopsy could be ideal recourse for examination to predict chemo-sensitivity in gastric cancer.

Citing Articles

Components of the human-specific, p53-mediated "kill switch" tumor suppression mechanism are usurped by human tumors, creating the possibility of therapeutic exploitation.

Nyce J Cancer Drug Resist. 2022; 2(4):1207-1214.

PMID: 35582271 PMC: 9019199. DOI: 10.20517/cdr.2019.89.

Delayed processing of blood samples impairs the accuracy of mRNA-based biomarkers.

Wilson C, Dias N, Pancini S, Mercadante V, Biase F Sci Rep. 2022; 12(1):8196.

PMID: 35581252 PMC: 9113984. DOI: 10.1038/s41598-022-12178-5.

Photonic technologies for liquid biopsies: recent advances and open research challenges.

DellOlio F, Su J, Huser T, Sottile V, Cortes-Hernandez L, Alix-Panabieres C Laser Photon Rev. 2022; 15(1).

PMID: 35360260 PMC: 8966629. DOI: 10.1002/lpor.202000255.

Gastric Cancer with Radiographically Occult Metastatic Disease: Biology, Challenges, and Diagnostic Approaches.

Sanjeevaiah A, Park H, Fangman B, Porembka M Cancers (Basel). 2020; 12(3).

PMID: 32150838 PMC: 7139817. DOI: 10.3390/cancers12030592.

The Prospect and Challenges to the Flow of Liquid Biopsy in Africa.

Temilola D, Wium M, Coulidiati T, Adeola H, Carbone G, Catapano C Cells. 2019; 8(8).

PMID: 31404988 PMC: 6721679. DOI: 10.3390/cells8080862.

References

Shen J, Wei J, Wang H, Yue G, Yu L, Yang Y . A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer. J Transl Med. 2013; 11:73. PMC: 3639168. DOI: 10.1186/1479-5876-11-73. View

Silva J, Rodriguez R, Garcia J, Munoz C, Silva J, Dominguez G . Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut. 2002; 50(4):530-4. PMC: 1773179. DOI: 10.1136/gut.50.4.530. View

Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L . ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer. 2008; 8:97. PMC: 2394535. DOI: 10.1186/1471-2407-8-97. View

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F . Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358(1):36-46. DOI: 10.1056/NEJMoa073149. View

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N . Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2014; 26(1):141-148. DOI: 10.1093/annonc/mdu472. View

Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V . Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2009; 99(6):923-9. PMC: 2538768. DOI: 10.1038/sj.bjc.6604629. View

Baldus S, Schaefer K, Engers R, Hartleb D, Stoecklein N, Gabbert H . Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010; 16(3):790-9. DOI: 10.1158/1078-0432.CCR-09-2446. View

Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez J . mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst. 2011; 103(20):1552-6. DOI: 10.1093/jnci/djr326. View

10.

Sugimoto N, Fujitani K, Imamura H, Uedo N, Iijima S, Imano M . Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402). Anticancer Res. 2014; 34(2):851-7. View

11.

Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M . S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9(3):215-21. DOI: 10.1016/S1470-2045(08)70035-4. View

12.

Salazar F, Molina M, Sanchez-Ronco M, Moran T, Ramirez J, Miguel Sanchez J . First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer. 2010; 72(1):84-91. DOI: 10.1016/j.lungcan.2010.07.008. View

13.

Wong S, Lo S, Cheung M, Ng K, Tse C, Lai B . Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. Clin Cancer Res. 2004; 10(5):1613-7. DOI: 10.1158/1078-0432.ccr-1168-3. View

14.

Shen J, Wang H, Wei J, Yu L, Xie L, Qian X . Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer. Int J Cancer. 2012; 131(6):E938-45. DOI: 10.1002/ijc.27530. View

15.

Terrin L, Rampazzo E, Pucciarelli S, Agostini M, Bertorelle R, Esposito G . Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res. 2008; 14(22):7444-51. DOI: 10.1158/1078-0432.CCR-08-0478. View

16.

Wesolowski R, Lee C, Kim R . Is there a role for second-line chemotherapy in advanced gastric cancer?. Lancet Oncol. 2009; 10(9):903-12. DOI: 10.1016/S1470-2045(09)70136-6. View

17.

Nabeya Y, Suzuki T, Furuya A, Koide N, Ohkoshi M, Takiguchi M . Calpain regulates thymidylate synthase-5-fluoro-dUMP complex levels associated with response to 5-fluorouracil in gastric cancer cells. Cancer Sci. 2011; 102(8):1509-15. PMC: 11158892. DOI: 10.1111/j.1349-7006.2011.01978.x. View

18.

Shen J, Wei J, Guan W, Wang H, Ding Y, Qian X . Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer. J Transl Med. 2014; 12:355. PMC: 4302091. DOI: 10.1186/s12967-014-0355-2. View

19.

Badalian G, Barbai T, Raso E, Derecskei K, Szendroi M, Timar J . Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status. Pathol Oncol Res. 2007; 13(2):99-104. DOI: 10.1007/BF02893484. View

20.

Monaco S, Nikiforova M, Cieply K, Teot L, Khalbuss W, Dacic S . A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol. 2009; 41(1):94-102. DOI: 10.1016/j.humpath.2009.06.019. View